NASDAQ$TBPH
Theravance Biopharma Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Theravance Biopharma reported bottom line performance driven by YUPELRI growth and expense management.
Theravance Biopharma announced its Q3 2023 financial results, highlighting YUPELRI growth and expense management leading to a non-GAAP loss of less than $1 million. The company is progressing with the Phase 3 CYPRESS study for ampreloxetine.
- Bottom line performance in Q3 was driven by YUPELRI growth and expense management.
- Non-GAAP loss of less than $1 million was reported.
- Phase 3 CYPRESS study for ampreloxetine is ongoing.
- Áine Miller, Ph.D., will assume the role of SVP, Development at Theravance Biopharma.
Headline financials
Revenue & EPS history
Theravance · Revenue · Quarterly
$15.7M
Revenue by segment
Theravance · $19.4K total across 1 segment · Q3 2022
- YUPELRI$19.4K—100.0%
Forward guidance
No specific financial guidance was provided in the current earnings report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
-0.4%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+0.5%
Avg return
30 days after
53%
26 / 49 earnings
Positive
+22.6%
Q3 2025
Best reaction
-20.0%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.9% | +2.0% | — | |
| Q1 2026 | +0.4% | -2.8% | -3.8% | |
| Q3 2025 | +22.6% | +15.3% | +17.2% | |
| Q2 2025 | +4.2% | +14.2% | +20.0% | |
| Q1 2025 | -9.0% | -15.1% | +13.6% | |
| Q4 2024 | +2.1% | +0.2% | +1.7% | |
| Q3 2024 | +6.6% | +4.8% | +8.7% | |
| Q2 2024 | -18.8% | -20.5% | -16.6% | |
| Q1 2024 | +0.1% | -1.0% | -7.9% | |
| Q4 2023 | +7.9% | +5.1% | +0.3% | |
| Q3 2023 | +2.8% | +1.3% | +6.3% | |
| Q2 2023 | -2.1% | +0.2% | -4.0% | |
| Q1 2023 | +0.4% | -0.3% | -1.4% | |
| Q4 2022 | +9.4% | +2.0% | +8.6% | |
| Q3 2022 | +4.0% | +13.2% | +7.4% | |
| Q2 2022 | -5.4% | -2.6% | +1.4% | |
| Q1 2022 | -9.5% | -10.5% | -12.0% | |
| Q4 2021 | +6.3% | +7.8% | +4.0% | |
| Q3 2021 | +7.1% | +12.7% | -2.1% | |
| Q2 2021 | -5.9% | -5.9% | -36.4% | |
| Q1 2021 | -1.5% | -0.6% | -15.6% | |
| Q4 2020 | -3.3% | -8.4% | +10.7% | |
| Q3 2020 | -13.4% | -3.6% | -12.0% | |
| Q2 2020 | -11.9% | -15.8% | -15.8% | |
| Q1 2020 | -2.5% | +3.8% | -6.7% | |
| Q4 2019 | -10.5% | +0.6% | +0.7% | |
| Q3 2019 | +0.9% | +3.3% | +23.3% | |
| Q2 2019 | +6.4% | -0.1% | +10.8% | |
| Q1 2019 | -11.8% | -12.8% | -37.8% | |
| Q4 2018 | +1.0% | -0.5% | -7.0% | |
| Q3 2018 | -1.5% | +7.5% | +14.1% | |
| Q2 2018 | +17.3% | +20.3% | +21.0% | |
| Q1 2018 | +5.4% | +7.2% | +1.1% | |
| Q4 2017 | -8.4% | +0.7% | -15.7% | |
| Q3 2017 | -4.3% | -0.7% | -10.6% | |
| Q2 2017 | -20.0% | -19.3% | +3.8% | |
| Q1 2017 | +1.5% | -4.6% | -3.4% | |
| Q4 2016 | +1.0% | +5.9% | +22.2% | |
| Q3 2016 | +17.6% | +32.1% | +17.6% | |
| Q2 2016 | +3.0% | +6.2% | +15.6% | |
| Q1 2016 | +5.1% | — | — | |
| Q4 2015 | -0.3% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +0.4% | — | — | |
| Q1 2015 | +3.0% | — | — | |
| Q4 2014 | -6.9% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -7.5% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro